Mostrar el registro sencillo del ítem

dc.contributor.authorMingot-Castellano, M Eva
dc.contributor.authorRoman, M Teresa Alvarez
dc.contributor.authorFernandez Fuertes, Luis Fernando
dc.contributor.authorGonzalez-Lopez, Tomas Jose
dc.contributor.authorGuinea de Castro, Jose Maria
dc.contributor.authorJarque, Isidro
dc.contributor.authorLópez Fernández, María Fernanda 
dc.contributor.authorLozano, Maria Luisa
dc.contributor.authorSanchez Gonzalez, Blanca
dc.contributor.authorFerreiras, David Valcarcel
dc.contributor.authorGonzalez Porras, Jose Ramon
dc.date.accessioned2022-01-25T12:16:54Z
dc.date.available2022-01-25T12:16:54Z
dc.date.issued2019
dc.identifier.issn1687-9104
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724426/pdf/AH2019-4621416.pdfes
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31534457es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15915
dc.description.abstractBackground and Objective: Diagnosis and management of primary immune thrombocytopenia (ITP) have changed dramatically in the last decade. The aim of the study was to obtain information about the opinion of the Spanish ITP Group (GEPTI) members regarding the best clinical practices for diagnosis and management of adult patients with ITP. Materials and Methods: A two-round Delphi method was carried out by sending to 129 experts a 90-item questionnaire developed by 11 specialists, with a 4-point Likert scale ("never," "sometimes," "frequently," and "always") for the assessment of responses. Results: Forty out of the 129 experts participated in the survey (participation rate 30.2%) and 39 completed the questionnaire (response rate 97.5%). Salient consensus points included the following: the need to indicate workup studies from a sustained platelet count < 100 x 10(9)/L in the absence of a clear etiology; bone marrow aspiration in elderly patients with suspected ITP; beginning treatment in asymptomatic patients with a platelet count < 20 x 10(9)/L; not exceeding 6-7 weeks of corticosteroid therapy; switching from corticosteroids to one thrombopoietin receptor agonist (TRA); switching to other TRA or other options as combinations of them with immunosuppressive drugs in case of failure; how to reduce tapering TRA; treating patients with symptomatic persistent ITP and platelet count > 20 x 10(9)/L; and considering mucosal or severe bleeding as a basic criterion for hospital admission. Conclusions: The present consensus document provides a reference framework for the management of patients with ITP in clinical practice.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleManagement of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Groupen
dc.typeArtigoes
dc.identifier.doi10.1155/2019/4621416
dc.identifier.pmid31534457
dc.identifier.sophos32350
dc.journal.titleAdv Hematoles
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña:: Hematoloxía clínicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Biomédica da Coruña (INIBIC)es
dc.rights.accessRightsopenAccesses
dc.subject.keywordCHUACes
dc.subject.keywordINIBICes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number2019.es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional